{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-022334","form_type":"8-K","ticker":"CLNN","cik":"0001822791","company_name":"Clene Inc.","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.359402+00:00","generated_at":"2026-06-22T05:50:29.142545+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Clene reports Q3 net loss $11.0M; ALS survival benefit >90% and MS trial meet endpoints","bullets":["Net loss of $11.0M ($0.17/share) vs net income $28.9M in Q3 2021; R&D $6.4M, G&A $3.6M.","Cash & securities $16.2M at Sep 30; subsequent $10.8M equity raise and $5.0M loan commitment.","ALS Healey trial: CNM-Au8 30 mg showed >90% reduction in risk of death at 24 weeks (p=0.028-0.075).","VISIONARY-MS Phase 2 met primary LCLA endpoint (p=0.056) and secondary mMSFC (p=0.0207).","Received EU Orphan Drug Designation for CNM-Au8 in ALS; ZnAg COVID trial topline Q4 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-022334","json":"https://secwatch.observer/filing/0000950170-22-022334.json","markdown":"https://secwatch.observer/filing/0000950170-22-022334.md","text":"https://secwatch.observer/filing/0000950170-22-022334.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822791/000095017022022334/0000950170-22-022334-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822791/000095017022022334/clnn-20221107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:50:29.142545+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9ad156ae75371243f42ba4202203b6e96e4b07af","claim":"Clene Inc. reported the quarter ended September 30, 2022 results: net income $11.0 million, EPS $0.17 per share.","evidence_excerpt":"Clene reported a net loss of $11.0 million, or $0.17 per share, for the quarter ended September 30, 2022, compared to net income of $28.9 million, or $0.47 per basic share and $0.42 per diluted share, for the same period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822791/000095017022022334/0000950170-22-022334-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Net income","value":"$11.0 million"},{"label":"EPS","value":"$0.17 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}